

(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 17<sup>th</sup> March, 2021

**ORDER**

S. O. 1237(E):- In the S.O. 4538(E) dated 18.12.2019, for the phrase “The price of the Synchronobreathe Inhaler Device as specified in column (5) of the above said table would remain fixed irrespective of the subsequent change in the ceiling price of the formulation (a) Budesonide 200mcg+ Formeterol 6mcg per dose Inhaler 120 MDI and (b) Budesonide 400mcg+ Formeterol 6mcg per dose Inhaler 120 MDI of M/s Cipla Ltd.” mentioned in Note (e) it is to be read as follows “The price revision based on Wholesale Price Index (WPI) as per para 16 of DPCO, 2013 would be applicable on the price of the Synchronobreathe Inhaler Device as specified in column (5) of the above said Table from the next year”.

2. All other notes and contents mentioned in the S.O. 4538(E) dated 18.12.2019 shall remain the same and are applicable.

PN/216/84/2021/F

F. No. 8(84)/2021/DP/NPPA-Div.-II

(Prasenjit Das)  
Deputy Director